Related Experiment Video
Updated: May 21, 2026
12:04
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
Neuroendocrine tumor disease: an evolving landscape
Andrea Frilling1, Goran Akerström, Massimo Falconi
1Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, UK.
Endocrine-Related Cancer
|May 31, 2012
Summary
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are increasing, often diagnosed late due to vague symptoms. Novel biomarkers and prognostic tools are needed for better GEP-NENs management and treatment.
Area of Science:
- Oncology
- Gastroenterology
- Endocrinology
Background:
- Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a diverse tumor group with rising incidence and prevalence.
- Vague or absent symptoms frequently lead to delayed diagnosis of GEP-NENs.
- Current biomarkers like Chromogranin A and Ki-67 have limitations for grading and therapy decisions.
Purpose of the Study:
- To review the current understanding and management strategies for gastroenteropancreatic neuroendocrine neoplasms.
- To highlight challenges in diagnosis and the need for improved prognostic tools.
- To discuss advancements in imaging and therapeutic options for GEP-NENs.
Main Methods:
- Literature review of gastroenteropancreatic neuroendocrine neoplasms.
- Analysis of diagnostic biomarkers and grading systems.
- Evaluation of current and emerging treatment modalities including surgery, somatostatin analogs, chemotherapy, and targeted therapies.
Main Results:
- GEP-NENs incidence and prevalence have significantly increased over the past 30 years.
- Somatostatin receptor (SSTR) imaging aids in diagnosis and staging.
- While curative options exist for localized disease, most GEP-NENs present with metastatic disease.
- Somatostatin analogs, chemotherapy (streptozotocin, temozolomide, capecitabine), and targeted agents (everolimus, sunitinib) show efficacy in specific GEP-NEN subtypes.
Conclusions:
- Accurate diagnosis and staging of GEP-NENs remain challenging due to nonspecific symptoms.
- Multidimensional prognostic nomograms require validation for improved patient management.
- Surgical resection and endoscopic ablation offer cure for early-stage disease.
- Advanced therapies, including targeted agents and somatostatin analogs, are crucial for managing metastatic GEP-NENs.
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...